Lineage Cell Therapeutics
LCTX
LCTX
114 hedge funds and large institutions have $85.6M invested in Lineage Cell Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.07% more ownership
Funds ownership: 50.01% → 50.08% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less capital invested
Capital invested by funds: $94.2M → $85.6M (-$8.57M)
Holders
114
Holding in Top 10
3
Calls
$58K
Puts
$1K
Top Buyers
| 1 | +$326K | |
| 2 | +$291K | |
| 3 | +$272K | |
| 4 |
Barclays
London,
United Kingdom
|
+$145K |
| 5 |
RA
Raffles Associates
New York
|
+$136K |
Top Sellers
| 1 | -$577K | |
| 2 | -$350K | |
| 3 | -$212K | |
| 4 |
Millennium Management
New York
|
-$169K |
| 5 |
Jane Street
New York
|
-$111K |